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Abstract 
The aim of this study was to evaluate patients on oral 
anticoagulants about their experience of life quality 
following different oral surgery interventions. 
The study consisted of 260 patients referred for oral 
surgical treatment. An equal number of patients were 
assigned to each group (60 individuals). Group 1 was 
with deep venous thrombosis, group 2 was with myo-
cardial infarct, group 3 with cerebrovascular insult, 
and group 4 with artificial heart valves. Control group 
consisted of 20 healthy individuals. After performing 
the oral surgery interventions, all patients were given 
a questionnaire with 15 questions to evaluate their 
quality of life for ten days after the oral surgery inter-
ventions. The local hemostasis was realized by applied 
three different local modalities: tranexamic acid 5%, 
sorbacel gauze, Tachocomb - fibrin glue. The statistical 
evaluation included descriptive and analytical meth-
ods (Kruskal - Wallis test). 
The average time needed for completion the surgical 
procedure was approximately 30 minutes. The results 
showed that patients in group 1 reported significant-
ly more pain on the first and second day after the in-
terventions. The bleeding index showed no statistical 
differences in the study groups. The results showed 
statistical difference between the four groups after 24 
h (H = 13.248; p = 0.0113), after 48 h (H = 0.425; p = 
0.0338) and after 7 days (H = 9.7603 p = 0.0447), and no 
statistical difference between the four groups after ten 
days (H = 4.2327 p = 0.3754).
The management of oral surgery procedures on pa-
tients treated with oral anticoagulants should be in-
fluenced by several factors: laboratory values, extent 
and urgency of the intervention, treating physician’s 
recommendation, available facilities, dentist exper-
tise, and patient’s oral, medical, and general condition. 
There is need more scientific investigation about life 
quality of oral anticoagulated patients following oral 
surgical procedure. 
Key words: Oral surgery, Oral anticoagulants, Quality of 
life, Local hemostasis, Pain.
1. Introduction
Arterial and venous thromboembolism is still the most 
frequent cause of morbidity and mortality in high- and 
middle-income countries, as well as in emerging econ-
omies. Thrombosis and the complicating embolism 
that can result are among the most important causes 
of sickness and death in developed countries. Throm-
bosis is of greater overall clinical importance in terms 
of morbidity and mortality than all of the hemorrhagic 
disorders combined. Excessive activation of coagula-
tion or inhibition of anticoagulant mechanisms may 
result in hypercoagulability and thrombosis. Injury to 
the vessel wall, alterations in blood flow, and changes 
in the composition of blood are major factors leading 
to thrombosis [1]. 
Vitamin K is a fat-soluble vitamin and serves as a 
co-factor for production of clotting factors: II, VII, IX, X, 
protein C, S, and Z. it has been reported to aid in bone 
and cartilage metabolism [2, 3]. The primary sources 
of vitamin K-contain foods are dark green vegetables 
and oils. Other source of vitamin K include processed 
foods and fast food because of the oils used in their 
production [4]. The term oral anticoagulant (OAC) re-
fers to oral vitamin K antagonists, including mainly 
sodium warfarin (the most widely used agent in An-
glo-Saxon countries) and acenocoumarol (widely used 
in some countries of Europe) [5]. Oral anticoagulants 
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are the group of drugs used to treat many cardiovascu-
lar diseases. The vitamin K antagonists, among which 
are warfarin and acenocoumarol, have low therapeutic 
index as its pharmacological management is difficult 
and need continuous monitoring, also have multiple 
interactions with other drugs and food. Many of the 
patients being treated with warfarin have an inade-
quate anticoagulation [6]. 
The anticoagulant effect in turn depends on the half-
life of the inhibited factors. In this sense, the half-lives 
of factors VII, IX, X and II are 6, 24, 40 and 60 hours, re-
spectively. Blood coagulation factor VII is the first to be 
affected, prolonging prothrombin time (PT). Factors IX, 
X and II are posterior affected: factor IX prolongs acti-
vated partial thromboplastin time (aPTT), while factors 
X and II prolong both PT and aPTT. These are well tol-
erated drugs, with rapid absorption via the oral route. 
The peak plasma concentrations are reached one hour 
after administration, though the reduction in coagula-
tion factors takes place 48 - 72 hours after dosing. The 
half-life of warfarin is 48 - 72 hours, versus 8 - 10 hours 
in the case of acenocoumarol. Thus, the effects of war-
farin are longer lasting in terms of both the induction 
and disappearance of therapeutic action [5, 7 - 9]. 
The oral and maxillofacial surgeons are frequently asked 
to manage patients who are receiving oral anticoagu-
lants. The goal of treatment is to minimize the risk of 
hemorrhage while continuing to protect the patient 
against thromboembolism formation. The ordinary 
treatment includes the interruption of anticoagulant 
therapy for oral surgery interventions to prevent hemor-
rhage. However, this practice may logically increase the 
risk of a potentially life-threatening thromboembolism. 
Thus, this issue is still controversial [10 - 13]. 
The aim of this study was to evaluate patients on oral 
anticoagulants about their experience of life quali-
ty following different oral surgery interventions. The 
specific intention was to highlight the evidence of oral 
anticoagulants interaction with food, herbs and di-
etary supplements and to highlight the areas of major 
concern, as well as to suggest specific practical steps 
to minimize their potential interactions with the tradi-
tional and the new oral anticoagulants. 
2. Materials and Methods 
The study consisted of 260 patients of both sexes (137 
males and 123 females) aged 60.1 (± 8,1 years) referred 
for oral surgical treatment at the Department of Oral 
and Maxillofacial Surgery and Dental Implantology, 
at the Faculty of Medical Science, “Goce Delcev” Uni-
versity, Stip, Macedonia. The study was approved by 
the Faculty Ethics Committee. The patients have been 
asked for anamnestic data, clinical examinations were 
performed, as well as radiograph analysis. Informed 
consent was obtained from all patients included in 
the study. Medical and dental history, age gender and 
tooth number were recorded for each patient. All oral 
surgery interventions were performed in the morning 
by one and the same operator. 
An equal number of patients were assigned to each 
group (60 individuals). Group 1 was with deep ve-
nous thrombosis (DVT), group 2 was with myocardial 
infarct (MI), group 3 with cerebrovascular insult (CVI) 
and group 4 with artificial heart valves (AHV). Control 
group consisted of 20 healthy individuals aged 42.8 (± 
8.2 years). The patient’s average international normal-
ized ratio value (INR) was 2.00 (± 0.27). The local he-
mostasis was realized by applied three different local 
modalities: tranexamic acid 5%, sorbacel gauze, and 
tachocomb - fibrin glue. 
After performing the oral surgery interventions, all 
patients were given postoperative instructions verbal-
ly by the operator and in a written form. At the same 
day, each patients received a questionnaire with 15 
questions to evaluate their quality of life with 5-point 
scale, ranging from 1 (“not at all”) to 5 (“very much”) for 
ten days after the oral surgery interventions (Table 1). 
The questionnaire included questions about limitation 
(ability to chew and speak, day activity and sleeping), 
prolonged bleeding, swelling, pain, bad taste/breath 
and nausea. Patients had to contact the surgeons if 
they experienced bleeding, severe pain or swelling. 
The statistical evaluation included descriptive and an-
alytical methods (Kruskal - Wallis test). 
Table 1. Quality of life questionnaire
No Questions Answers*
1 Do you have bleeding? 
2 Do you have swelling?
3 Do you have bruises?
4 Do you feel nausea?
5 Do you feel a bad taste or breath?
6 What is the worst pain that you felt?
7 What is the average degree of pain that you felt?
8 Did you take any pain-killers today?
9 Do you experience any difficulties with mouth opening?
10 Do you experience any difficulties with chewing
11 Are there any foods that you can’t eat now?
12 Do you experience any difficulties with speaking?
13 Do you experience any difficulties with sleeping?
14 Have you missed your work/school?
15 Do you experience any difficulties with your daily activities?
*Answers for day 1 to 10:
Not at all (1); Very little (2); Some (3); Quite a bit (4); Very much (5). 
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3. Results and Discussion 
3.1 Results 
There were no significant differences of patients ac-
cording to age, gender, tooth diagnosis and the site of 
operation between four groups. 
The average time need to complete the oral surgery 
procedures for group 1 (DVT) and group 3 (CVI) were ap-
proximately 25 (range 17 to 33 minutes), for group 2 (MI) 
approximately 35 (range 20 to 45 minutes), for group 4 
(АVH) approximately 30 (range 20 to 45  minutes). 
Table 2 presents different complications first, second and 
seventh day after oral surgery treatment. The bleeding in-
dex showed no statistical differences in the study groups 
(Table 3). The results showed statistical difference be-
tween the four groups: after 24h (H = 13.248; p = 0.0113), 
after 48h (H = 0.425; p = 0.0338) and after 7 days (H = 
9.7603 p = 0.0447), and no statistical difference between 
the four groups after ten days (H = 4.2327 p = 0.3754). 
Table 2. Local complications first, second and seventh day after surgery
GROUP
LOCAL COMPLICATIONS AFTER 24h
pain swelling hematoma trismus dry socket other
G1 (DVT) = 60 17 (28%) 18 30%) 18 (30%) 5 (8%) 0 0
G2 (MI) = 60 8 (13%) 9 (15%) 14 (23%) 6 (10%) 6 (10%) 3 (5%)
G3 (CVI) = 60 3 (5%) 6(10%) 9 (15%) 3 (5%) 0 0
G4 (AHV) = 60 8 (13%) 11(18%) 14 (23%) 0 0 0
KG = 20 0 5 (25%) 3 (15%) 0 0 0
Total 260 36 (14%) 49 (19%) 58 (22%) 14 (5%) 6 (2%) 3(1%)
GROUP
LOCAL COMPLICATIONS AFTER 48 h
pain swelling hematoma trismus dry socket other
G1 (DVT) = 60 4 (7%) 5 (8%) 12 (20%) 0 4 (7%) 0
G2 (MI) = 60 3 (5%) 1 (2%) 10 (17%) 0 0 0
G3 (CVI) = 60 3 (5%) 0 6 (10%) 1(2%) 0 0
G4 (AHV) = 60 0 7 (12%) 7 (12%) 0 0 0
KG = 20 0 2 (10%) 4 (20%) 1(5%) 0 0
Total 260 10 (4%) 15 (6%) 39 (15%) 2 (0.8%) 4 (1.5%) 0
GROUP
LOCAL COMPLICATIONS AFTER 7 days
pain swelling hematoma trismus dry socket other
G1 (TDV) = 60 0 5 (8%) 2 (3%) 0 2 (3%) 0
G2 (MI) = 60 0 5 (8%) 0 1 (2%) 1 (2%) 0
G3 (CVI) = 60 0 3 (5%) 0 0 0 0
G4 (VSV) = 60 0 2 (3%) 8 (14%) 0 0 0
KG = 20 0 0 0 0 0 0
Total 260 0 15 (6%) 10 (4%) 1 (0.4%) 3 (1%) 0
Legend:
DVT - deep venous thrombosis
MI - myocardial infarct
CVI - cerebrovascular insult
AHV - artificial heart valves
There were no significant differences of bleeding 
24 hours after oral surgery treatment between the 
groups, Kruskal - Wallis - test of rang sum was H = 
9.0122 p = 0.0608. Bleeding index is showed on Ta-
ble 3. Kruskal - Wallis - test of rang sum showed that 
there were no no significant differences of bleeding 
24 hours after oral surgery treatment between the 
four groups: G1 (DVT) H = 1.129 p = 0.5684; G2 (MI) 
H = 1.5324 p = 0.4648; G3 (CVI) H = 0.00 p = 1.0; G4 
(VSV) H = 1.5733 p = 0.4554); 
Table 4 presents the average values of patients’ experi-
ence for quality of life for four groups. Patients reported 
significant more difference and difficulties in average 
degree of pain postoperatively and 38% of the patients 
took analgesics after surgery. There were no significant 
differences of patients according to absence from work 
and difficulties with daily routine activities and 82% of pa-
tients reported different factors, such as day of treatment, 
type of occupation and design of insurance system. 
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Table 3. Bleeding index after oral surgery procedures
24h Bleeding index 0 Bleeding index 1 Total
G1 (DVT) 43 (72%) 17 (28%) 60 (100%)
G2 (MI) 49 (82%) 11 (18%) 60 (100%)
G3 (CVI) 48 (80%) 12 (20%) 60 (100%)
G4 (AHV) 45 (75%) 15 (25%) 60 (100%)
KG 20 (100%) 0 20 (100%)
Total 205 55 260
48h Bleeding index 0 Bleeding index 1 Total
G1 (DVT) 56 (93%) 4 (7%) 60 (100%)
G2 (MI) 55 (92%) 5 (8%) 60 (100%)
G3 (CVI) 56 (93%) 4 (7%) 60 (100%)
G4 (AHV) 53 (88%) 7 (12%) 60 (100%)
KG 20(100%) 0 20 (100%)
Total 240 20 260
Legend:
DVT - deep venous thrombosis
MI - myocardial infarct
CVI - cerebrovascular insult
AHV - artificial heart valves
Table 4. Patients’ experience for quality of life for four groups 
Question
Day
1 2 3 4 5 6 7 8 9 10
1. Bleeding 2,4 (±1,3) 2,2 (±1,3) 2,1 (±1,3) 2,0 (±1,2) 1,5 (±0,9) 1,3 (±0,3) 1,1 (±0,1) 1,1 (±0,1) 1,0  (±0) 1,0 (±0)
2. Swelling 3,3 (±1,3) 3,2 (±1,3) 2,9 (±1,3) 2,5 (±1,2) 1,8 (±0,5) 1,5 (±0,3) 0,3 (±0,3) 1,1 (±0,1) 1,0  (±0) 1,0  (±0)
3. Bruises 3,1 (±1,3) 3,3 (±1,3) 3,1 (±1,3) 3,1 (±1,5) 2,8 (±1,3) 2,5 (±1,5) 2,3 (±1,3) 1,5 (±0,3) 1,3 (±0,2) 1,0  (±0)
4. Nausea 1,8 (±0,3) 1,8 (±1,3) 1,5 (±0,2) 1,3 (±0,3) 1,3 (±0,3) 1,3 (±0,1) 1,2 (±0,3) 1,0 (±0,3) 1,0 (±0) 1,0  (±0)
5. Bad taste or breath 2,1 (±0,3) 2,1 (±0,3) 1,9 (±0,3) 1,8 (±0,3) 1,3 (±,53) 1,1 (±0,3) 1,0 (±0,3) 1,0 (±0,1) 1,0 (±0,1) 1,0 (±0)
6. The worst pain 3,8 (±1,3) 3,3 (±1,3) 3,1 (±1,3) 2,9 (±1,4) 2,5 (±1,5) 2,2 (±1,3) 1,9 (±0,9) 1,5 (±0,5) 1,3 (±0,8) 1,2 (±0,3)
7.
Average 
degree of 
pain 
4,3 (±1,3) 4,1 (±1,3) 4,1 (±0,9) 3,5 (±1,3) 3,3 (±1,5) 2,9 (±1,3) 2,1 (±1,4) 1,7 (±0,3) 1,3 (±0,7) 1,1  (±0)
8. Taking any pain-killers 2,9 (±2.7) 2,9 (±1,9) 2,7 (±1,5) 2,6 (±1,5) 2,5 (±1,1) 2,1 (±1,0) 1,6 (±0,9) 1,3 (±0,1) 1,1 (±0,3) 1,1 (±0,2)
9.
Difficulties 
with mouth 
opening? 
2,1 (±1,9) 2,0 (±1,8) 2,0 (±1,6) 1,9 (±1,4) 1,5 (±0,3) 1,4 (±0,4) 1,3 (±0,2) 1,2 (±0,2) 1,0 (±0,2) 1,0 (±0,1)
10.
Difficulties 
with 
chewing 
2,2 (±1,9) 2,0 (±1,8) 1,9 (±1,6) 1,8 (±1,4) 1,5 (±0,2) 1,3 (±0,4) 1,2 (±0,2) 1,2 (±0,2) 1,0 (±0,2) 1,0 (±0,1)
11. Difficulties with eating 2,0 (±1) 2,1 (±0,9) 1,8 (±0,3) 1,8 (±0,3) 1,7 (±0,3) 1,3 (±0,3) 1,3 (±0,1) 1,2 (±0,2) 1,1 (±0,1) 1,1 (±0,1)
12.
Difficulties 
with 
speaking? 
1,8 (±0,3) 1,8 (±0,3) 1,5 (±0,4) 1,3 (±0,3) 1,3 (±0,3) 1,2 (±0,1) 1,1 (±0,1) 1,1,3 (±0,1) 1,1 (±0,1) 1,1  (±0)
13.
Difficulties 
with 
sleeping 
3,3 (±1,9) 3,1 (±1,5) 3,1 (±1,3) 2,9 (±1,1) 2,5 (±1,3) 2,3 (±1,3) 2,1 (±1,3) 1,3 (±0,3) 1,1 (±0,3) 1,0 (±0,1)
14.
Missed 
work/
school?
3,8 (±1,9) 3,2 (±1,8) 3,3 (±1,3) 2,8 (±1,3) 2,8 (±1,1) 2,5 (±1,3) 2,3 (±0,3) 2,1 (±0,8) 1,3 (±0,3) 1,3 (±0,1)
15.
Difficulties 
with daily 
activities? 
3,3 (±1,3) 3,3 (±13) 2,9 (±1,3) 2,8 (±1,5) 2,5 (±0,3) 1,9 (±0,3) 1,7 (±0,3) 1,3 (±0,2) 1,2 (±0,2) 1,1 (±0,1)
Legend:
(1) Not at all.  (2) Very little. (3) Some. (4) Quite a bit. (5) Very much. 
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3.2 Discussion
3.2.1 Interruption and limitations of oral  anticoagulants
Assael [14] said that the hemostasis care of the oral 
anticoagulated patients is a shared responsibility and 
oral and maxillofacial surgeons, and the hematology/
coagulation team huddle to determine the steps. The 
surgeon is faced with the choice of altering or stopping 
oral anticoagulants and risking thromboembolism or 
leaving the patient on the oral anticoagulants and 
risking uncontrolled bleeding. A common approach to 
managing patients with a low risk of thromboembo-
lism needing surgery is to interrupt oral anticoagulants 
therapy for several days before and after surgery. Pa-
tients with a high risk of thromboembolism commonly 
stop OAC and bridge anticoagulation with unfraction-
ated heparin (UHF) or low-molecular-weight heparin 
(LMWH) [15]. Depending on the existing thromboem-
bolic risk, the American Heart Association/American 
College of Cardiology Foundation Guide to Warfarin 
Therapy recommends different heparin management 
regimens for the patients with moderate, high and low 
thromboembolic risk. In general, heparins are not rein-
troduced before 12 hours post-surgery and dosing is 
postponed for longer periods in the case of evidence 
of bleeding [16]. 
However, patients who interrupt oral anticoagulants 
therapy are at risk of developing a thromboembolism 
with or without bridging therapy. On the other hand, 
oral anticoagulants therapy can be continued without 
interruption for procedures such as dentoalveolar sur-
geries that rarely cause significant or life-threatening 
bleeding. Stopping oral anticoagulants is problematic 
because of its slow unpredictable reversal [17 - 21]. 
The goal of managing anticoagulated patients who 
need surgery is to prevent major or life-threatening 
bleeding while protecting against thromboembolism. 
Some procedures such as intra-abdominal, intratho-
racic, major cancer surgery, removal of head and neck 
tumors, and extra oral open reduction of facial frac-
tures are associated with considerable bleeding [22 - 
24]. Some patients are particularly sensitive to OACs, 
and the activity of these drugs moreover can be affect-
ed by a range of factors including individual patient 
response, diet, or the simultaneous administration of 
other commonly used drugs such as antibiotics, anal-
gesics, or even herbal remedies [9]. 
The ACCP 2008 guidelines for antithrombotic and 
thrombolytic therapy recommend in patients who 
require a minor dental procedure, continuing OKAs 
with an oral prohemostatic agent or stopping VKAs 
Table 5. Vitamin K (phylloquinone) content in common vegetables 
Food Serving size Vitamin K classification content (mcg) (per serve)
Alfalfa 1/4 cup 10 Low
Asparagus 4 spears 30 Medium
Beans (green) 1/2 cup 11 Low
Broccoli (cooked) 1/2 cup 110 High
Brussel sprouts 1/2 cup 114 High
Cabbage (cooked) 36 1/2 cup 36 Medium
Capsicum (green) 9 1 capsicum 9 Low
Carrot 1/2 cup 11 Low
Cauliflower 3 florets 7.5 Low
Lettuce (gourmet) e.g. butter lettuce 1 cup 97 High
Lettuce (Iceberg) 1 cup 13 Low
Mushrooms (cooked) 1 cup 0.2 Low
Parsley 10 sprigs 164 High
Peas (frozen, cooked) 1/2 cup 24 Low
Potatoes 1 potato 3 Low
Pumpkin 1/2 cup 1 Low
Silverbeet (cooked) 1/2 cup 346 High
Soybeans (cooked, boiled) 1/2 cup 16 Low
Soya milk 1/2 cup Low 4** Low
Spinach (cooked) 1/2 cup 444 Low
Spinach (raw) 1 cup 150 High
Sweet potato (cooked, baked) 1 potato 3.4 Low
Tomatoes 1 tomato 10 Low
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(warfarin) 2 to 3 days before the procedure instead of 
alternative strategies [25]. Local methods to prevent or 
control bleeding are several: local pressure (biting on 
gauze or tea bags); site packing (Gelfoam™, Surgicel™, 
Avitene™), additional suturing, electrocautery, topical 
thrombin, mouth rinse(s) of cold water or aminocapro-
ic acid 5% mouth rinse (5 grams in 100 mL of sterile wa-
ter). Hemorrhage is common complication after dental 
surgery in oral anticoagulated patients, as well as pain 
and swelling during the postoperative period [26].
3.2.2 Traditional oral anticoagulants and food
Since traditional oral anticoagulants (warfarin) act by 
reducing activity of Vitamin K in blood clotting pro-
cesses, a large change in patient intake of vitamin K, 
either through dietary source of mineral supplements, 
may disrupt the beneficial effects of warfarin. Most 
people taking warfarin experience no problems relat-
ed to the amount of vitamin K in their diet. However, 
if excessive amount of vitamin K-rich foods are con-
sumed, the effect of warfarin may be reduced, resulting 
in decrease in INR. Conversely, a reduction in Vitamin K 
intake could increase the effect of warfarin, leading to 
an increase in bleeding and INR levels. As a result, it is 
recommended that people taking warfarin try to keep 
their intake of Vitamin K-rich foods relatively stable in 
order to prevent INR [27]. 
High amounts of vitamin K are generally found in 
green leafy vegetables, such as spinach, broccoli, silver 
beet (Table 5) [28]. In contrast, all breads, cereal grains 
and their products, nuts, most fruits, fish, meat, chick-
en, pork, tofu, eggs, dairy products, fats and oils, roots 
and tubers contain low quantities of Vitamin K. 
Herbal teas that contain coumarin derivatives such as 
tonka beans, melilot (sweet clover) and sweet wood-
ruff may also interfere with warfarin and therefore are 
best avoided (Table 6). People taking oral anticoagu-
lants should eat a normal, balanced diet and maintain 
a consistent amount of vitamin K intake. Ideally it is 
recommended that daily variation in intake of Vitamin 
K-rich foods not exceed 250 - 500 micrograms [29 - 33]. 
There are some other important dietary tips:
•• Not to eat grapefruit or drink grapefruit juice. Grape-
fruit and grapefruit juice decrease the body’s ability 
to metabolize coumadin.
Table 6. List of possible interactions between herbal medicines and warfarin 
Herbal / mineral supplement
(common name)
Potential effects on Warfarin and 
blood coagulation Potential effect on INR
Chamomile Increased anticoagulant effect INR could increase
Cranberry juice Increased anticoagulant effect INR could increase
Danshen Increased anticoagulant effect INR could increase
Devil’s claw Increased anticoagulant effect INR could increase
Dong Quai Increased anticoagulant effect INR could increase
Fenugreek Increased anticoagulant effect INR could increase
Feverfew Increased anticoagulant effect INR could increase
Fish oils (Omega-3) Increased anticoagulant effect INR could increase
Garlic (capsules) Increased anticoagulant effect INR could increase
Gingko Biloba Increased anticoagulant effect INR could increase
Ginseng May reduce the effect of Warfarin INR may decrease
Green Tea May reduce the effect of Warfarin INR may decrease
Saw palmetto Increased anticoagulant effect INR could increase
St. John’s Wort May reduce the effect of Warfarin INR may decrease
Iron, Magnesium, Zinc supplements No effect likely, if taken 2 hours apart from Warfarin No change
Glucosamine/chondroitin Unlikely to have an effect, but could potentially increase bleeding INR could increase
Co-enzyme Q10 May reduce the effect of Warfarin INR may decrease
Vitamin B family No effects reported No change
Vitamin C3 (Ascorbic acid) Unlikely to have any effect No change
Vitamin E3 (Tocopherol) Unlikely to have an effect, but could potentially increase bleeding INR could increase
Vitamin K (Phylloquinone) Will reduce the effect of Warfarin INR reading may decrease
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•• Alcohol can change the response to coumadin. 
•• Avocados  are high in vitamin K, although the 
amount varies from avocado to avocado. Vitamin 
K content in guacamole can vary by as much as 40 
times. Because avocados can unpredictably affect 
the PT/INR, it may be best to avoid them.
•• Although  dried basil, thyme and oregano  contain 
high levels of vitamin K, a teaspoon of these herbs 
in their fresh form contain only a small amount and 
can be used.
•• Store-bought margarine contains unknown amounts 
of various vegetable oils. As a result, the amount of 
vitamin K in these foods is unpredictable. 
•• Store-bought mayonnaise  also contains unknown 
amounts of various vegetable oils and therefore 
has an unpredictable vitamin K content. Mayon-
naise should be homemade with oils that are low-
er in vitamin K. If store-bought products are used, 
they should be the “light” variety with only small 
portions consumed (such as no more than several 
teaspoons).
•• For the same reasons as with margarine and mayon-
naise, be cautious of store-bought salad dressings. 
Homemade dressings are preferred.
•• Exposing oils to sunlight  or fluorescent light de-
stroys about 85% of vitamin K. Expose high vitamin 
K oils to light for at least 48 hours by placing them in 
a transparent container in the sunlight. 
•• The vitamin K content of food is not altered by cook-
ing or gamma irradiation.
•• Some daily multi-vitamins contain vitamin K. 
•• Vitamins A, E and possibly C may also affect couma-
din works [31 - 34]. 
The authors advise the food mentioned in Table 5 and 
Table 6 should be avoided before major and minor sur-
gery, because food in Table 5 decreases the effect of 
oral anticoagulants and the food and herbal medicines 
in table 6 increases or reduces it. In general, the food 
and herbal medicines listed in the tables should be 
consumed in moderation.
4. Conclusions
- The currently available anticoagulant agents all target 
thrombin or FXa, either indirectly or directly. Thrombin 
is a logical target because of its multiple roles in coag-
ulation.
- The management of oral surgery and other surgery pro-
cedures on patients treated with anticoagulants should 
be influenced by several factors: laboratory values, ex-
tent and urgency of the intervention, treating physician’s 
recommendation, available facilities, dentist expertise, 
and patient’s oral, medical, and general condition. 
- The use of some vegetables, herbs and dietary sup-
plements in patients taking anticoagulants needs to 
be routinely assessed and documented. Patients need 
to be educated about the risk versus the benefits of 
such food and supplements. 
- Special care needs to be undertaken in patients un-
dergoing various surgical interventions as use of some 
foods, herbs and supplements can increase the risk of 
bleeding. It is necessity to avoid and discontinue all 
dietary supplements at least one-two week prior to 
surgery. 
- Education of healthcare professional and the patients 
is crucial. As a recommendation is to avoid and mini-
mize the interaction of food and dietary supplements 
in order to allow for more stable and safe anticoagula-
tion of patients treated with oral anticoagulants.
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